GFAP and Alzheimer disease: GFAP measured in serum is increased in AD and correlates with cognitive decline.211 Temporal profiles of serum NfL levels are associated with cognitive decline212 and can predict clinical progression even in pre-symptomatic AD.213 At present, levels of BBs of brain injury in COVID-19 patents are unknown.